ABOUT ABOUT

We’re solving an enormous real-world problem by helping patients take their medications properly

Every day, millions of people fail to take their medications as prescribed and the resulting personal and financial costs are staggering. Worldwide, non-adherence results in $700 billion in avoidable medical costs.

The data we create is unique and has enormous value to pharmaceutical companies, researchers and governments.

Every time a patient uses our CuraServe technology, our data grows in utility and value.

Curaizon™ solves drug non-adherence problem by deploying our technology through national health services. As part of our solution, we collect fully anonymized data about how and when patients take medications.

CuraTokens™ are the only way to access our data. Tokens can be redeemed to access the data, which will advance medical research, drive down healthcare costs and save lives.

The value of a CuraToken™ is based on a real solution to a real problem.









Curaizon™ Ecosystem
graph

TOKEN TOKEN

CuraToken™ Utility Tokens (CTKN) allow the token holder to access our proprietary and anonymized medical data on the blockchain.

CuraTokens™ are the only way to access Curaizon’s™ technology.

CuraToken™ holders can access data which utilizes powerful, predictive analytics, AI and big data in the fight against drug non-adherence.

CuraTokens™ provide real time analysis on patient behavior and adherence.

CuraTokens™ enable the use of blockchain technology to manage authentication, confidentiality and accountability by allowing individuals to be in control of their data, providing protection, security and compliance with all upcoming, required regulations, including GDPR.

CuraTokens™ facilitate partnerships with medical and pharmaceutical organizations through a token reward system.

CuraToken™ holders know they are saving lives around the world by helping to solve the problem of drug non-adherence.



RoadMap Roadmap

January 2016

CuraServe™ Development Begins

June 2017

CuraServe™ Testing Underway

February 2018

CuraData™ Alpha Release Complete

June 1st 2018

Token Presale Begins

June 8th 2018

Token Public Sale Begins

September 2018

CuraData™ Beta Release Complete

January 2018

CuraServe™ Public Release

May 2019

CuraData™ Platform Growth

2020

Curadata™ 2.0 Release

Media Media

See where you might have seen us.

TEAM TEAM

Our team combines passion, innovation and expertise with experience in healthcare, finance, operations, marketing and technology

LEADERSHIP

Nicholas James Rumble

Chief Executive Officer (CEO)

Nicholas James Rumble

Chief Executive Officer (CEO)

Nicholas has a background in mathematics and economics and spent much of his working life inside investment banking. Most recently he was responsible for Saxo Bank’s Asia Pacific and Australasian operations. He was heavily engaged in both retail and institutional client relationships and was instrumental in pioneering new trading technologies. He brings more than 20 years of business experience and knows how to bring great teams of people together and execute high-level plans; especially where technology plays a key role.

team

Chris Matey

Chief Financial Officer (CFO)
team

Chris Matey

Chief Financial Officer (CFO)

Chris has an MBA in finance as well as a JD. He has experience as a financial analyst, director and executive as well as experience across startup and technology companies as well as an entrepreneur. In his roles at OrderTrust™ and CyberCash™ he developed high-volume payment related products deployed around the world. In his work as a consultant he has worked with a wide variety of companies around the world providing strategic analysis and fundraising support.

team

Darran Trute

Chief Technology Officer (CTO)
team

Darran Trute

Chief Technology Officer (CTO)

Darran has delivered a range of IT solutions for clients ranging from blue chip companies to not for profits. He currently specializes in blockchain related projects providing technical expertise to address real world issues. Darran also has extensive experience in pioneering health sector redesign to meet the considerable demands of an aging population with multiple, complex health needs.

team

Andrey Verbitsky

ICO Director
team

Andrey Verbitsky

Tokenomics Expert

Andrey has designed more than 80 tokens and is widely considered a leading expert in token economics and crypto-currencies. He has consulted across a range of industries, advising on ICO’s and blockchain application strategies to drive business impact and bring value to investors, founders, and end users.

He brings enormous experience and expertise in technology, economics and behavioral science with over 20 years’ experience in telecommunications, product management and consulting, working with multiple Tier 1 clients across the globe.

team

Luke Lerdal

Chief Data Officer (CDO)
team

Luke Lerdal

Chief Data Officer (CDO)

Luke has an extensive background in data modeling and systems. He has led complex data analysis projects with an emphasis on big data. His responsibilities include overseeing the data integration and data structure of CuraServe™ and CuraData™.

TECHNOLOGY

team

Gateway Technolabs

Software Development
team

Gateway Technolabs

Software Development

A global information technology services, solutions and product engineering company with a team of brilliant and dedicated professionals serving our customers across 30 countries in 5 continents.

team

Innohead

Big Data & Predictive Analytics
team

Innohead

Big Data & Predictive Analytics

A Big Data and Predictive Analytics company focused on data mining and customer analytics.

team

Timengo

IoT, Cloud and security experts
team

Timengo

IoT, Cloud and security experts

Timengo are IoT, Cloud and security experts with a wealth of knowledge and experience within the healthcare sector. They drive our internal and external technology applications and help us to deliver secure API infrastructure with external databases.

team

CLX

Tier-1 CPaaS provider
team

CLX

Tier-1 CPaaS provider

CLX are the only tier-1 CPaaS provider trusted to to carry over 25 billion transactions per year and are our notification partner.

ADVISORS

team
Rory McCrea
MB BS, MSc, MRCGP
team

Rory McCrea

MB BS, MSc, MRCGP

Rory has been described by the UK’s Financial Times as a “Health Entrepreneur”. He gained this reputation for his farsighted innovation as Chairman of ChilversMcCrea Healthcare, co-founding and overseeing, from startup in 2001 through to successful transfer in 2010 to a Trade Partner, a network of over 40 NHS General Practices and Urgent Care services across England and Wales. Rory has also been highly influential in the public sector having been a Medical Director with NHS West Essex for over a decade before becoming Director of Clinical Transformation with The West Essex Clinical Commissioning Group. Rory will be a driving force behind the adoption of Curaizon's™ technology across multiple national healthcare services. Rory has been an advisory board member of Curaizon's™ since 2015.

team
Sarah Chilvers
BSc, RGN, RHV, MBA, DProf
team

Sarah Chilvers

BSc, RGN, RHV, MBA, DProf

Sarah has spent her life working in, and with, the UK’s National Health Service. First as a registered nurse and a health visitor and then in NHS management. Sarah went on to complete her Professional Doctorate at The Middlesex University in 2004, specializing in new ways of delivering healthcare and has been working to drive innovation and clinical excellence for more than 25 years. Winner of the Laing and Buisson Independent Healthcare Award in 2008 for Entrepreneurial Achievement, Sarah has a perfect mix of clinical and business experience that has proven invaluable in her advisory role at Curaizon™ since 2015. She is responsible for integrating our clinical trials and the adoption of our technologies across multiple national health services.

team
Parexel
Biopharmaceutical service provider
team

Parexel

Biopharmaceutical service provider

Parexel International is a global provider of biopharmaceutical services. It conducts clinical trials on behalf of its clients to expedite the approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. Parexel are our clinical trial partners in the UK and will deliver bridging studies for entry into each new territory.

FAQ FAQ

We aim to improve drug adherence and bring game-changing benefits to patients and healthcare providers by being the leading supplier of adherence and data solutions worldwide.

Our solution works with patients, their families and healthcare providers to ensure that patients take their medications as prescribed through a series of outreach tools, supported by predictive modeling tools and behavioural analysis, to increase the rate of drug adherence

Our CuraServe technology helps ensure that patients take their medicines as prescribed by their doctor. By doing this, we help patients live longer and healthier lives. We also reduce the healthcare costs that occur when patients fail to take their medications properly.

Our CuraServe™ technology generates a tremendous amount of unique, real-time data showing how people take their medications that is very valuable to a variety of groups including pharmaceutical companies, medical researchers and biotech companies. CuraTokens™ allow token owners access to the data to make queries. As our solution is rolled out to more and more patients in more and more countries. The more data we generate, the more valuable that CuraTokens™ become.

Curaizon™ sells its adherence (CuraServe™) solutions to national health services around the world. Our end users are the health service's patients who take any form of medication. We also work with academia, pharmaceutical and biotech industries, as well as other users of data via our CuraData™ solution.

Curaizon targets countries with national health services. This currently includes 1.4 Billion people and that number is growing.

The global cost of non-adherence is over €600 billion each year and results in hundreds of thousands of lives lost prematurely. Adherence for chronic and long-term illness is less than 50%.

Contact Contact

Any question? Reach out to us and we’ll get back to you shortly.

info@curaizon.com